Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RESMED, INC.

(RMD)
  Report
Delayed Nyse  -  04:00 2022-10-04 pm EDT
228.73 USD   +2.00%
09/19Insider Sell: Resmed
MT
09/14Transcript : ResMed Inc. Presents at BofA Securities Global Healthcare Conference 2022, Sep-14-2022 08:05 AM
CI
09/12Transcript : ResMed Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 08:45 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RBC Downgrades ResMed to Sector Perform From Outperform, Citing Valuation, But Lifts Price Target to $252 From $246, Calls Fiscal Q4 'Solid'

08/12/2022 | 08:08am EDT


© MT Newswires 2022
All news about RESMED, INC.
09/19Insider Sell: Resmed
MT
09/14Transcript : ResMed Inc. Presents at BofA Securities Global Healthcare Confer..
CI
09/12Transcript : ResMed Inc. Presents at Morgan Stanley 20th Annual Global Health..
CI
09/09North American Morning Briefing: Stocks to Gain; -2-
DJ
09/07Insider Sell: Resmed
MT
09/07ResMed Announces Participation in the Bank of America Global Healthcare Conference
GL
09/07ResMed Announces Participation in the Bank of America Global Healthcare Conference
GL
09/06ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conf..
GL
09/06ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conf..
GL
09/04Over 480 Million People Estimated to Have COPD, World's Third Deadliest Disease, ResMed..
AQ
More news
Analyst Recommendations on RESMED, INC.
More recommendations
Financials (USD)
Sales 2023 3 996 M - -
Net income 2023 907 M - -
Net Debt 2023 480 M - -
P/E ratio 2023 37,0x
Yield 2023 0,79%
Capitalization 33 494 M 33 494 M -
EV / Sales 2023 8,50x
EV / Sales 2024 7,66x
Nbr of Employees 8 160
Free-Float 77,1%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 228,73 $
Average target price 253,00 $
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Michael J. Farrell Director-Business Development
Robert Andrew Douglas Vice President-Corporate Marketing
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RESMED, INC.-12.19%33 494
THERMO FISHER SCIENTIFIC-19.08%204 878
DANAHER CORPORATION-15.18%195 530
INTUITIVE SURGICAL, INC.-43.91%69 051
BOSTON SCIENTIFIC CORPORATION-6.12%57 093
EDWARDS LIFESCIENCES CORPORATION-32.71%52 980